Filipsson Nyström [80] is currently conducting the only interventional trial in patients with pituitary adenomas to quantify and compare rates of [68Ga]Ga-DOTATOC uptake between tumors and normal pituitary tissue, and secondarily to correlate tracer uptake rates to SSTR2 expression, to report adverse events, and to detect post-surgery tumor recurrences. Here, SSTR2 is linked to neoplasm.